Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Autism Spectrum Disorders

NCT01064973 is registered in ClinicalTrials.gov with Seaside Therapeutics, Inc. as lead sponsor.

NCT NCT01064973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01064973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Autism Spectrum Disorders
Lead sponsor
Seaside Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2010
Completion date
December 31, 2012
Enrollment
32 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorders